ArticleBlood advances2025

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study.

Beatrice Casadei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.